Literature DB >> 16412749

Preliminary prospective study of the endocrinology of conception cycles and early pregnancy in women with antiphospholipid syndrome treated with low molecular weight heparin.

Alka Prakash1, Susan Laird, Tin C Li, William L Ledger.   

Abstract

OBJECTIVE: To examine whether there were any differences in the endocrinological profiles during conception cycle and early pregnancy between a control group and women with a history of recurrent miscarriage that was caused by antiphospholipid syndrome and that was treated with aspirin and low molecular weight heparin.
DESIGN: Prospective observational study.
SETTING: Recurrent Miscarriage Clinic, Department of Obstetrics and Gynaecology in a tertiary care centre. PATIENT(S): Five women with recurrent pregnancy loss were recruited as cases, whereas another five women having natural cycle donor insemination were used as control. INTERVENTION(S): Serial measurement of serum beta-hCG, activin A, and inhibin A was performed from postovulatory day 12 until 11 weeks of gestation. MAIN OUTCOME MEASURE(S): Comparison of levels of beta-hCG, activin A, and inhibin A at the time of conception onwards till 11 weeks in the two groups. RESULT(S): There were no significant differences between the two groups. CONCLUSION(S): There does not appear to be any obvious endocrinological alteration in the conception cycle of women with antiphospholipid syndrome compared with a control group. Furthermore, the initiation of heparin does not produce a significant change in activin A and inhibin A levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412749     DOI: 10.1016/j.fertnstert.2005.07.1288

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

Review 1.  Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review.

Authors:  Lei Ni; Xue-Qian Sun; Dong-Xu Zhao; Zi-Wei Zhu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.